DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/jl9dv2/spinal_muscular_at) has announced the addition of Global Markets Direct's new report "Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2012" to their offering.
Global Markets Direct's, 'Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2012', provides an overview of the Spinal Muscular Atrophy (SMA) therapeutic pipeline. This report provides information on the therapeutic development for Spinal Muscular Atrophy (SMA) , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) .
'Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope:
- A snapshot of the global therapeutic scenario for Spinal Muscular Atrophy (SMA) .
- A review of the Spinal Muscular Atrophy (SMA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Spinal Muscular Atrophy (SMA) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- News and deals relating to the products.
Reasons to Buy:
- Identify and understand important and diverse types of therapeutics under development for Spinal Muscular Atrophy (SMA) .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA) pipeline depth and focus of Spinal Muscular Atrophy (SMA) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
For more information visit http://www.researchandmarkets.com/research/jl9dv2/spinal_muscular_at
Source: Global Markets Direct